Patents Assigned to Collagen Corporation
  • Patent number: 5475052
    Abstract: The present invention discloses collagen-synthetic polymer matrices which are prepared using a multiple step reaction. The first step of the reaction generally involves reacting collagen with a functionally activated synthetic hydrophilic polymer to form a collagen-synthetic polymer matrix. The synthetic hydrophilic polymer may be mono- or multifunctionally activated, but is preferably difunctionally activated, resulting in the formation of a crosslinked collagen matrix. The second step comprises modifying the collagen-synthetic polymer matrix according to one or more of the following methods: further crosslinking the matrix using a multifunctionally activated synthetic polymer, conjugating the matrix using a monofunctionally activated synthetic polymer, coupling biologically active molecules or glycosaminoglycans to the matrix, crosslinking the matrix using conventional chemical crosslinking agents, or modifying the collagen in the matrix by means of various chemical reactions.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: December 12, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5470911
    Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: November 28, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5446091
    Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.
    Type: Grant
    Filed: January 5, 1995
    Date of Patent: August 29, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5428022
    Abstract: A human placental collagen composition for use in soft tissue augmentation comprising an aqueous suspension of a homogenized nonirradiation-sterilized mixture of type I and type III human placental collagen, wherein the type III collagen constitutes less than about 10% by weight of the mixture.
    Type: Grant
    Filed: July 29, 1992
    Date of Patent: June 27, 1995
    Assignee: Collagen Corporation
    Inventors: Howard Palefsky, Bruce B. Pharriss, George Chu
  • Patent number: 5428024
    Abstract: High concentration collagen compositions having improved persistence when administered for soft tissue augmentation are prepared from both cross-linked and non-cross-linked collagen starting materials. Suspensions of the starting materials are subjected to vigorous mechanical disruption to reduce the average collagen fiber size to below a threshold level which enhances the injectability of the composition. Thus, both enhanced injectability and enhanced persistence may be achieved using the same formulations.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: June 27, 1995
    Assignee: Collagen Corporation
    Inventors: George Chu, Brenda Trobaugh, Prema Rao
  • Patent number: 5425770
    Abstract: Processes for the preparation of compositions used in conductive bone repair are disclosed. The compositions contain a mixture consisting essentially of either a calcium phosphate particulate mineral component or particulate hydroxyapatite in admixture with atelopeptide reconstituted fibrillar collagen. The method is comprised of mixing a dispersion of the collagen and mineral, the latter which is present in dry particulate form, followed by molding and drying the composition in a mold to obtain a dried composition.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: June 20, 1995
    Assignee: Collagen Corporation
    Inventors: Karl A. Piez, Bruce B. Pharriss, George H. Chu, Thomas L. Smestad, Diana Hendricks
  • Patent number: 5413791
    Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: May 9, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5383930
    Abstract: A device for correcting fine superficial facial lines which comprises a syringe fitted with a 31-33 gauge needle and an aqueous suspension of noncrosslinked fibrillar atelopeptide collagen contained within the syringe barrel, the concentration of collagen in the suspension being in the range of 10 to 50 mg/ml and the suspension exhibiting an extrusion plot in which there is a smooth substantially linear increase in force up to a substantially constant force in the range of 5 to 30 newtons.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: January 24, 1995
    Assignee: Collagen Corporation
    Inventors: Ann Brannan, Roseann Burhenne, Frank A. Delustro, Thomas L. Smestad, Louis Fries, Rees M. Orland
  • Patent number: 5376375
    Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
    Type: Grant
    Filed: January 5, 1994
    Date of Patent: December 27, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5366498
    Abstract: A device for correcting fine superficial facial lines which comprises a syringe fitted with a 31-33 gauge needle and an aqueous suspension of noncrosslinked fibrillar atelopeptide collagen contained within the syringe barrel, the concentration of collagen in the suspension being in the range of 10 to 50 mg/ml and the suspension exhibiting an extrusion plot in which there is a smooth substantially linear increase in force up to a substantially constant force in the range of 5 to 30 newtons.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: November 22, 1994
    Assignee: Collagen Corporation
    Inventors: Ann Brannan, Roseann Burhenne, Frank A. Delustro, Thomas L. Smestad, Louis Fries, Rees M. Orland
  • Patent number: 5352715
    Abstract: Injectable implant compositions comprise a biocompatible ceramic matrix present in a fluid carrier, where the ceramic matrix comprises particles having a size distribution in the range from 50 .mu.m to 250 .mu.m. Optionally, the compositions may further comprise collagen, where the relative amounts of collagen and ceramic matrix at least partly determine the physical properties of implants formed by injecting the compositions. The fluid carrier is an aqueous buffered medium, typically including an organic polymer base material when there is no collagen present in the composition. The compositions are particularly suitable for repair and augmentation of soft and hard tissues by injection.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: October 4, 1994
    Assignee: Collagen Corporation
    Inventors: Donald G. Wallace, Hugh McMullin, George Chu
  • Patent number: 5328955
    Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: July 12, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5324775
    Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: June 28, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5308889
    Abstract: Medical articles in the form of strings are formed by covalently binding collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugate formulations which are extruded to make the strings. The collagen may be recombinantly produced human collagen or collagen extracted from any source, such as a bovine source or human placenta, and purified and can be of various types and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 20,000. The string can be designed to incorporate other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The strings contain large amounts of water when extruded and may then be dehydrated to form relatively solid but flexible strings.
    Type: Grant
    Filed: December 2, 1992
    Date of Patent: May 3, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Louis Fries, Ramesh Damani, Kimberly McCullough, Frank DeLustro
  • Patent number: 5306500
    Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: April 26, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5304595
    Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
    Type: Grant
    Filed: December 30, 1992
    Date of Patent: April 19, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5292802
    Abstract: Medical articles in the form of tubes are formed by covalently binding collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugate formulations which are used to make the tubes. The collagen may be recombinantly produced human collagen or collagen extracted from any source, such as a bovine or human placental source, and purified and can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The tube can be designed to incorporate other components such as liquid, pharmaceutically acceptable, carriers, and/or biologically active proteins such as growth factors or cytokines. The tubes contain large amounts of water when extruded and then may be dehydrated to form relatively solid but flexible tubes which can be easily stored.
    Type: Grant
    Filed: December 2, 1992
    Date of Patent: March 8, 1994
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Kimberly McCullough
  • Patent number: 5264214
    Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
    Type: Grant
    Filed: August 14, 1992
    Date of Patent: November 23, 1993
    Assignee: Collagen Corporation
    Inventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
  • Patent number: 5258029
    Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.
    Type: Grant
    Filed: May 23, 1990
    Date of Patent: November 2, 1993
    Assignee: Collagen Corporation
    Inventors: George H. Chu, Rosa Armstrong, Robert Chang
  • Patent number: 5246457
    Abstract: A composition for use in bone repair, in particular, in only procedures, which comprises calcium phosphate mineral particles in admixture with atelopeptide reconstituted fibrillar collagen preparations is disclosed. This composition is non-immunogenic and encourages the fusion of host bone with new bone growth through the implant. Additional processes for curing the implant to improve its compressive strength include heat curing, maturation, and cross-linking.
    Type: Grant
    Filed: December 17, 1990
    Date of Patent: September 21, 1993
    Assignee: Collagen Corporation
    Inventors: Karl A. Piez, Bruce B. Pharriss, George H. Chu, Thomas L. Smestad, Diana Hendricks